Conversely, in NSCLC, high PD-L1 expression was more frequently observed in KRAS-mutated tumors compared with KRAS-WT (65.3% v 58.5%, OR = 1.34, and FDR-P = .0002). This evidence concerns the gene KRAS and non-small cell lung carcinoma.